Patient-reported health-related quality of life with apremilast for psoriatic arthritis: A phase ii, randomized, controlled study

Journal of Rheumatology

Volumn 40, Issue 7, 2013, Pages 1158-1165

  Strand, Vibeke ^a   Schett, Georg ^b   Hu, ChiaChi ^c   Stevens, Randall M ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c CELGENE CORPORATION   (United States)

Author keywords

Clinical Trials; Psoriatic Arthritis; Quality Of Life; Spondyloarthropathy; Visual Analog Scale

Indexed keywords

APREMILAST; METHOTREXATE; PLACEBO;

ADULT; ARTHRALGIA; ARTICLE; ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFECT; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHYSICAL PARAMETERS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; TREATMENT DURATION; VISUAL ANALOG SCALE;

CLINICAL TRIALS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SPONDYLOARTHROPATHY; VISUAL ANALOG SCALE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; DISABILITY EVALUATION; FATIGUE; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84879984872     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121200     Document Type: Article

References (42)

1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14-ii17.
2. National Psoriasis Foundation. Report on the psycho-social impacts of psoriasis. Portland, OR: National Psoriasis Foundation; 2009 [Internet. Accessed March 7, 2012.] Available from: Www.psoriasis.org/NetCommunity/Document.Doc?id= 619
3. Singh JA, Strand V. Spondyloarthritis is associated with poor function and physical health-related quality of life. J Rheumatol 2009;36:1012-20.
4. Wallenius M, Skomsvoll JF, Koldingsnes W, Rodevand E, Mikkelsen K, Kaufmann C, et al. Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis 2009;68:685-9.
5. Brodszky V, Balint P, Geher P, Hodinka L, Horvath G, Koo E, et al. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int 2009;30:199-205.
6. Zhu TY, Tam LS, Leung YY, Kwok LW, Wong KC, Yu T, et al. Socioeconomic burden of psoriatic arthritis in Hong Kong: Direct and indirect costs and the influence of disease pattern. J Rheumatol 2010;37:1214-20.
7. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Dermatol Venereol 2000;80:430-4.
8. Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology 2012;51:571-6.
9. Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012;17:1143-50.
10. Kavanaugh A, Antoni C, Krueger GG, Yan S, Bala M, Dooley LT, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006;65:471-7.
11. Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: A randomized, placebo-controlled, phase II trial. Curr Med Res Opin 2010;26:2385-92.
12. Heiberg MS, Kaufmann C, Rodevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 2007;66:1038-42.
13. Saurat JH, Guerin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, et al. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: Associated clinical and economic outcomes in real-world practice. Dermatology 2010;220:128-37.
14. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008;67:855-9.
15. New guidelines for managing psoriasis with systemic medications. Dermatol Nurs 2009;21:301-3.
16. Brunasso AM, Puntoni M, Salvini C, Delfino C, Curcic P, Gulia A, et al. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: A study of 103 Italian patients. Acta Dermatol Venereol 2011;91:44-9.
17. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M. Cyclic AMP: Master regulator of innate immune cell function. Am J Respir Cell Mol Biol 2008;39:127-32.
18. Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 2004;84:137-67.
19. Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 2007;6:17-26.
20. Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159:842-55.
21. Salari P, Abdollahi M. Phosphodiesterase inhibitors in inflammatory bowel disease. Expert Opin Investig Drugs 2012;21:261-4.
22. Heystek HC, Thierry A-C, Soulard P, Moulon C. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol 2003; 15:827-35.
23. Claveau D, Chen SL, O'Keefe S, Zaller DM, Styhler A, Liu S, et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2- hydroxypropan-2-yl)-phenyl]-ethyl] 3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2004; 310:752-60.
24. Papp K, Cather J, Rosoph L, Sofen H, Langley RG, Matheson RT, et al. The efficacy of apremilast, a phosphodiesterase-4 inhibitor, in the treatment of moderate to severe psoriasis: Results of a phase 2 randomised study. Lancet 2012;380:738-46.
25. Schett G, Wollenhaupt J, Papp K, Joos R, DeVlam KL, Rodrigues JF, et al. Oral apremilast is effective in the treatment of subjects with active moderate to severe psoriatic arthritis: Results of a multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2012;64:3156-67.
26. Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008;24:1529-38.
27. Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology 2010;49:1900-10.
28. Strand V, Bombardier C, Maetzel A, Scott D, Crawford B. Use of minimum clinically important differences (MCID) in evaluating patient responses to treatment of rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001;44 Suppl:S187.
29. Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, et al. Physical function and health related quality of life: Analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005;32:590-601.
30. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811-9.
31. Kwok T, Pope JE. Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. J Rheumatol 2010;37:1024-8.
32. Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: Relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 2011;38:2461-5.
33. Strand V, Crawford B, Singh J, Choy E, Smolen JS, Khanna D. Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis 2009;68:1800-4.
34. Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 2008;11:1131-43.
35. Ara R, Brazier J. Predicting the Short Form-6D preference-based index using the eight mean Short Form-36 health dimension scores: Estimating preference-based health-related utilities when patient level data are not available. Value Health 2009;12:346-53.
36. Ware J, Kosinski M, Dewey JE. How to score version 2 of the SF-36 health survey. Lincoln, RI: QualityMetric Inc.; 2000.
37. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates Inc.; 1988.
38. Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: A comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009;7:25.
39. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6:383-92.
40. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64.
41. Reich A, Hrehorow E, Szepietowski JC. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol 2010;90:257-63.
42. Strand V, Hu A, Day R, Sloan V. Improved quality of life with apremilast (APR) in the treatment of psoriasis: Results from a phase IIb randomized controlled study [abstract P3337]. J Am Acad Dermatol 2011;64 Suppl 1:AB154.